Vandetanib
- Generic Name
- Vandetanib
- Brand Names
- Caprelsa
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24BrFN4O2
- CAS Number
- 443913-73-3
- Unique Ingredient Identifier
- YO460OQ37K
- Background
Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.
On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
- Indication
Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.
- Associated Conditions
- Metastatic Thyroid Gland Medullary Carcinoma, Locally advanced Medullary thyroid cancer
ZD6474 to Treat Advanced Brain Cancer in Patients
- Conditions
- Recurrent High-Grade GliomasProgressive Low-Grade GliomasMalignant Gliomas
- First Posted Date
- 2006-01-05
- Last Posted Date
- 2019-12-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 83
- Registration Number
- NCT00272350
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2003-10-16
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Genzyme, a Sanofi Company
- Registration Number
- NCT00071188
- Locations
- 🇹🇭
Research Site, Chiang mai, Thailand
ZD6474 in Treating Patients With Small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Genzyme, a Sanofi Company
- Registration Number
- NCT00066313
- Locations
- 🇨🇦
British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦British Columbia Cancer Agency - Centre for the Southern Interior, Kelowna, British Columbia, Canada
🇨🇦Saint John Regional Hospital, Saint John, New Brunswick, Canada
This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2003-05-05
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 160
- Registration Number
- NCT00059722
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.
- Conditions
- Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line
- First Posted Date
- 2002-10-24
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 129
- Registration Number
- NCT00047840
- Locations
- 🇭🇺
Research Site, Torokbalint, Hungary
Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer
- Conditions
- Multiple Myeloma
- First Posted Date
- 2002-10-21
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 30
- Registration Number
- NCT00047788
- Locations
- 🇨🇦
Research Site, Montreal, Quebec, Canada
This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer
- Conditions
- Metastases, NeoplasmBreast Neoplasms
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 44
- Registration Number
- NCT00034918
- Locations
- 🇪🇸
Research Site, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.